Piper remains buyer of Inovio after management meetings

Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Inovio Pharmaceuticals with a $12 price target following a day of investor meetings with management. The analyst looks to 2019 efficacy updates for MEDI0457 and INO-5401 in combination with PD-(L)1 in head and neck, bladder cancer, and glioblastoma as validating for the Aspire platform. He continue to like the stock’s set-up and remain buyers of the shares.
https://thefly.com/landingPageNews.php?id=2795531